The impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patients

Basit Öğe Kaydı
dc.authoridyüce, Elif/0000-0002-3174-7129
dc.authorwosidUyanik, Mehmet/AAD-7345-2020
dc.authorwosidyüce, Elif/AFH-0870-2022
dc.contributor.authorUyanik, Mehmet S.
dc.contributor.authorPamuk, Gulsum E.
dc.contributor.authorMaden, Muhammet
dc.contributor.authorMerev, Elif
dc.contributor.authorCevik, Gokcen
dc.contributor.authorUyanik, Vesile
dc.contributor.authorUmit, Elif G.
dc.date.accessioned2024-06-12T11:13:12Z
dc.date.available2024-06-12T11:13:12Z
dc.date.issued2017
dc.departmentTrakya Üniversitesien_US
dc.description.abstractTreatment with tyrosine kinase inhibitors (TKIs) has dramatically changed the life expectancy of chronic myeloid leukaemia (CML) patients. Although the impact of first-generation TKIs on quality of life (QoL) was shown in CML, the effects of new generic formulations of imatinib mesylate (IM) are unclear. We evaluated differences in QoL under treatment with first-or second-generation TKIs. Fifty-two patients diagnosed with CP-CML completed the European Organization for Research and Treatment of Cancer Quality of Life Questionaire-C30, Hospital Anxiety and Depression Scale, and General Health Questionnaire. General QoL scores were similar between groups. There was a significant difference in the frequency of diarrhoea between IM group and the group using new generic formulations of IM (P = 0.012). General QoL score tended to be higher in patients with disease duration longer than 3 years (P = 0.052). GHQ, anxiety and depression scores correlated positively with symptom scales and negatively with functional subscales. CML patients using new generic formulations of IM reported a higher frequency of diarrhoea than patients using original IM and second-generation TKIs that could result in more drug discontinuation.en_US
dc.identifier.doi10.1111/ecc.12423
dc.identifier.issn0961-5423
dc.identifier.issn1365-2354
dc.identifier.issue2en_US
dc.identifier.pmid26594025en_US
dc.identifier.scopus2-s2.0-84947976354en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1111/ecc.12423
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23464
dc.identifier.volume26en_US
dc.identifier.wosWOS:000396457700010en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofEuropean Journal Of Cancer Careen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectQuality Of Lifeen_US
dc.subjectLeukaemiaen_US
dc.subjectTyrosine-Kinase Inhibitorsen_US
dc.subjectCancer-Patientsen_US
dc.subjectEortc Qlq-C30en_US
dc.titleThe impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu